Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Director Buys 25,000 Shares of Company Stock

Lineage Cell Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Director Deborah Andrews bought 25,000 shares at an average price of $0.80, spending $20,000 and increasing her direct stake by 160.48% to 40,578 shares.
  • Lineage shares traded at $0.82, near their 52-week low of $0.77 and below their 50- and 200-day moving averages. Quarterly EPS matched estimates at a loss of $0.03, while revenue of $1.43 million fell short of the $2.32 million consensus.
  • Analysts’ consensus rating is “Moderate Buy,” with an average price target of $6.25; four analysts rate the stock Buy and one rates it Hold.
  • MarketBeat previews top five stocks to own in December.

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Get Free Report) Director Deborah Andrews acquired 25,000 shares of the business's stock in a transaction dated Monday, November 16th. The stock was purchased at an average price of $0.80 per share, with a total value of $20,000.00. Following the completion of the transaction, the director directly owned 40,578 shares of the company's stock, valued at $32,462.40. This trade represents a 160.48% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Lineage Cell Therapeutics Stock Performance

Lineage Cell Therapeutics stock traded up $0.02 during midday trading on Tuesday, reaching $0.82. 6,784,316 shares of the stock were exchanged, compared to its average volume of 1,368,579. The company's fifty day moving average is $0.99 and its 200-day moving average is $1.29. The firm has a market cap of $206.32 million, a PE ratio of -9.06 and a beta of 1.68. Lineage Cell Therapeutics, Inc. has a 52 week low of $0.77 and a 52 week high of $1.99.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX - Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.03) EPS for the quarter, meeting the consensus estimate of ($0.03). The firm had revenue of $1.43 million during the quarter, compared to the consensus estimate of $2.32 million. Lineage Cell Therapeutics had a net margin of 16.18% and a return on equity of 3.37%. On average, sell-side analysts anticipate that Lineage Cell Therapeutics, Inc. will post -0.07 earnings per share for the current fiscal year.

Institutional Trading of Lineage Cell Therapeutics

Several institutional investors have recently added to or reduced their stakes in LCTX. StoneX Group Inc. lifted its position in Lineage Cell Therapeutics by 74.9% in the third quarter. StoneX Group Inc. now owns 29,747 shares of the company's stock valued at $30,000 after purchasing an additional 12,739 shares during the last quarter. Two Sigma Securities LLC grew its holdings in shares of Lineage Cell Therapeutics by 85.4% in the second quarter. Two Sigma Securities LLC now owns 37,793 shares of the company's stock worth $50,000 after purchasing an additional 17,403 shares during the last quarter. Equitable Holdings Inc. bought a new position in shares of Lineage Cell Therapeutics in the second quarter worth approximately $39,000. SummitTX Capital L.P. increased its stake in shares of Lineage Cell Therapeutics by 185.3% in the first quarter. SummitTX Capital L.P. now owns 60,833 shares of the company's stock worth $96,000 after buying an additional 39,514 shares during the period. Finally, State of Wyoming bought a new stake in Lineage Cell Therapeutics during the 2nd quarter valued at $57,000. 62.47% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Raymond James Financial reissued a "market perform" rating on shares of Lineage Cell Therapeutics in a research note on Friday. Four analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $6.25.

Read Our Latest Stock Analysis on Lineage Cell Therapeutics

About Lineage Cell Therapeutics

(Get Free Report)

Lineage Cell Therapeutics is a biotechnology company developing cell-based therapies for serious medical conditions. The company uses its cell therapy platform to create and manufacture specialized human cells intended to replace or support damaged cells and tissues. Its programs include OpRegen, a retinal pigment epithelial cell therapy being developed for retinal diseases; OPC1, an oligodendrocyte progenitor cell therapy for spinal cord injury; ANP1, an auditory neuron progenitor cell program for hearing loss; and VAC2, a cell-based cancer immunotherapy.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Lineage Cell Therapeutics Right Now?

Before you consider Lineage Cell Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lineage Cell Therapeutics wasn't on the list.

While Lineage Cell Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines